Stephen Hoge Sells 254 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 254 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $84.10, for a total value of $21,361.40. Following the completion of the transaction, the president now directly owns 1,442,357 shares in the company, valued at approximately $121,302,223.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Stephen Hoge also recently made the following trade(s):

• On Monday, July 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00.
• On Monday, June 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00.
• On Wednesday, May 29th, Stephen Hoge sold 341 shares of Moderna stock. The shares were sold at an average price of $144.50, for a total transaction of $49,274.50.

Moderna Stock Performance

Shares of MRNA opened at $82.25 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The company has a 50-day simple moving average of $118.88 and a two-hundred day simple moving average of $114.11. The firm has a market capitalization of $31.52 billion, a PE ratio of -5.25 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same period last year, the business posted ($3.62) earnings per share. Moderna’s quarterly revenue was down 29.9% compared to the same quarter last year. On average, analysts anticipate that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on MRNA shares. Piper Sandler restated an “overweight” rating and set a $157.00 price target (down from $214.00) on shares of Moderna in a research report on Friday, August 2nd. UBS Group upped their price target on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. The Goldman Sachs Group cut their price target on shares of Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, August 2nd. Evercore ISI restated an “in-line” rating and set a $120.00 price target on shares of Moderna in a research report on Thursday, June 27th. Finally, Canaccord Genuity Group upped their price target on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $124.21.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna during the second quarter valued at approximately $26,000. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna during the fourth quarter valued at approximately $27,000. Cedar Wealth Management LLC increased its position in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Westside Investment Management Inc. bought a new stake in shares of Moderna during the first quarter valued at approximately $32,000. Finally, Family Firm Inc. bought a new stake in shares of Moderna during the second quarter valued at approximately $33,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.